Bone cancer drug go-ahead
Thousands of cancer patients whose disease has spread to the bone could benefit from a new drug currently being approved for use on the NHS.
Denosumab (Xgeva) helps prevent bone complications in people whose cancer has spread from its original site.
New draft guidance from the National Institute for Health and Clinical Excellence (Nice), which is still subject to consulation, recommends the drug for certain groups of cancer patients whose disease has spread, most commonly the spine, pelvis, hip, upper leg bones and skull.